|Bid||0.00 x 1800|
|Ask||0.00 x 1800|
|Day's range||53.64 - 54.65|
|52-week range||46.48 - 64.21|
|Beta (5Y monthly)||0.15|
|PE ratio (TTM)||100.15|
|Forward dividend & yield||1.40 (2.58%)|
|Ex-dividend date||12 Aug 2021|
|1y target est||69.28|
In the last year, multiple insiders have substantially increased their holdings of AstraZeneca PLC ( LON:AZN ) stock...
(Bloomberg) -- AstraZeneca Plc has been studying options including a potential listing of its newly-created vaccines division as it seeks ways to boost returns for investors, people with knowledge of the matter said. Most Read from BloombergThe Hot New Trend For Hedge Funds Is—Finally—Female FoundersAutomating the War on Noise Pollution‘Ghost Signs’ Haunt London’s Reviving NeighborhoodsThe U.K. pharmaceutical giant is in the early stages of considering the best positioning for the vaccine unit,
The pharmaceutical is a high-quality dividend stock that offers investors tremendous growth at a reasonable price.